Cardiome's oxypurinol fails CHF Phase II

Cardiome (TSE:COM; CRME) said its oxypurinol missed the primary endpoint in the Phase II OPT-CHF trial to treat class III-IV chronic heart failure (CHF) (p=0.357). The double-blind, placebo-controlled...